Semaglutide, a flagship long-acting GLP-1 peptide API, is a core active pharmaceutical ingredient for antidiabetic and weight management formulations. Manufactured using a proprietary total-synthesis peptide process, the product achieves a purity of ≥99%. Trace impurities are strictly controlled in accordance with ICH and pharmacopeial quality standards, ensuring minimal batch-to-batch variation and highly consistent biological activity.
Produced under GMP-compliant cleanroom manufacturing conditions, the product is manufactured at stable kilogram-scale capacity and is supplied with a complete Certificate of Analysis (COA), comprehensive impurity profiling, and Drug Master File (DMF) documentation, fully supporting the development and regulatory submission of both injectable and oral formulations. Its long-acting molecular modification provides sustained therapeutic activity while maintaining stable glycemic control, prolonged satiety, and proven cardiovascular protective benefits. Semaglutide serves as a high-quality, compliant pharmaceutical ingredient for the development of generic and innovative therapeutics targeting metabolic diseases.